107P Health-related quality of life with ivonescimab versus pembrolizumab for PD-L1 positive, non-small cell lung cancer (HARMONi-2): A randomised, double-blind, phase III study in China
Randomised trial compares health-related quality of life in NSCLC patients treated with ivonescimab versus pembrolizumab, suggesting improvements with ivonescimab.
Key Points
The aim is to compare health-related quality of life between ivonescimab and pembrolizumab in patients with PD-L1 positive NSCLC.
Randomised, double-blind, phase III study design
Participants were previously untreated patients with advanced PD-L1 positive NSCLC
Comparison of health-related quality of life outcomes between treatments
Ivonescimab significantly improved progression-free survival compared to pembrolizumab
Safety profile of ivonescimab was manageable
Health-related quality of life data were reported from the study